Blincyto (blinatumomab)

P2, N=90, Not yet recruiting, SWOG Cancer Research Network

Vignettes explored access to evidence-informed but not universally funded therapies: blinatumomab for low-risk relapse of B-cell acute lymphoblastic leukemia (B-ALL), larotrectinib for TRK-fused soft tissue sarcoma, PBT for unresectable head-and-neck sarcoma, and tisagenlecleucel for first relapse of B-ALL in a patient with Down syndrome. Access to evidence-informed cancer therapies for Canadian children remains variable. Universal funding, simplified approval processes, and the establishment of Canadian PBT centres to reduce travel burden, would ensure timely, equitable access to high-cost therapies.

P2/3, N=340, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Oct 2029 --> Oct 2033 | Trial primary completion date: Feb 2029 --> Oct 2033

T-cell engager therapies, including bispecific T-cell engagers and the immune-mobilizing monoclonal T-cell receptor against cancer tebentafusp, are an emerging class of anticancer immunotherapy, with rapid expansion of the class since initial approval of blinatumomab in 2014 and with distinct dermatologic adverse events increasingly recognized across agents. Tebentafusp and talquetamab demonstrate highest rates of notable dermatologic toxicity reflecting on-target off-tumor cutaneous effects...Across agents, most dermatologic adverse events can be managed with topical corticosteroids, emollients, antihistamines, or brief courses of systemic corticosteroids without requiring treatment discontinuation. Recognition of these agent-specific and mechanistically linked patterns is essential for dermatologists as T-cell engager therapies become increasingly integrated into oncology practice.

Imaging flow cytometry verified conventional flow cytometry data showing increased T:B synapse and multimer formation after incubation with bispecific T cell engagers. Therefore, both flow cytometry platforms are suitable for identification of T cell: target cell conjugates.

P1, N=26, Not yet recruiting, Wake Forest University Health Sciences

P1/2, N=30, Not yet recruiting, M.D. Anderson Cancer Center

The introduction of BCR::ABL1 tyrosine kinase inhibitors (TKIs) transformed this disease, and more recently, chemotherapy-free regimens combining TKIs with the bispecific T-cell engager blinatumomab have achieved excellent long-term survival without routine allogeneic stem cell transplantation (allo-SCT)...These observations underscore that risk stratification in Ph+ ALL is not static but must be interpreted within the context of the specific treatment used. In this review, we examine the key prognostic determinants in Ph+ ALL, their evolving relevance across treatment eras, and the emerging risk-adapted strategies for treatment intensification in the chemotherapy-free era.

P3, N=303, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting

P1/2, N=50, Not yet recruiting, Novartis Pharmaceuticals | Trial completion date: Dec 2035 --> Jun 2036 | Trial primary completion date: Jan 2033 --> Jul 2033

There were no other notable differences in T-cell phenotype or markers of exhaustion among the subset of samples with extended flow cytometry panels. With the exception of lower CD4:CD8 ratios in patients with prior inotuzumab, the comparable apheresis yield and composition observed after immunotherapy exposure is a reassuring finding, particularly in light increased use of upfront blinatumomab for B-ALL.

P=N/A, N=92, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting --> Recruiting | N=30 --> 92